Clinical Trial for Pediatric Upper Limb Spasticity |XEOMIN®

Upper Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy

Pivotal Trial Design

  • Dose-response study of efficacy and safety of XEOMIN to treat spasticity of the upper limb(s)1

Coprimary outcome measures1

  • Change from baseline to Week 4 in:
    • AS of the primary clinical target pattern
    • GICS

Endpoints (OLEX phase)2

  • Change in AS score from baseline to 4th injection
  • Change in GICS from baseline to 4th injection
Outline of the XARA study design. Pinch to zoom Study Table Pinch to zoom

References

  1. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2020.
  2. Data on file. Raleigh, NC: Merz North America, Inc.; 2021.